{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:27:19Z","timestamp":1787563639443,"version":"build-2736575974"},"reference-count":40,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:p>Background: Neurofilament light (NfL) can reflect the extent of neuron\/axon damage, thus providing an opportunity to examine the severity and progression of the diseases with such damage. Objective: Whether serum NfL can be used as an indicator to monitor the cognitive progress of de novo Parkinson\u2019s disease (PD) remains unclear. Methods: In this research, 144 healthy controls and 301 de novo PD patients from Parkinson\u2019s Progression Markers Initiative (PPMI) were recruited. Linear mixed effects models were used to examine the associations of baseline\/longitudinal serum NfL with cognitive decline. Cox regression was used to detect cognitive progression in PD participants. Results: We found PD patients had higher serum NfL than controls at baseline (p\u200a=\u200a0.031), and NfL increase was faster in PD group (p\u200a&lt;\u200a0.001). Both baseline serum NfL and its rate of change predicted measurable cognitive decline in early PD (MoCA, \u03b2=\u200a\u20130.014, p\u200a&lt;\u200a0.001; \u03b2=\u200a\u20130.002, p\u200a&lt;\u200a0.001, respectively). Additionally, we observed that NfL levels were also able to predict progression in different diagnostic groups and Amyloid- PD and Amyloid+PD groups. After an average follow-up of 6.37\u00b11.84 years, the baseline NfL of the third tertile of high concentrations was associated with a future high risk of PD dementia (adjusted HR 6.33, 95% CI 2.62\u201315.29, p\u200a&lt;\u200a0.001). Conclusion: In conclusion, our results indicated that the serum NfL concentration could function as an easily accessible biomarker to monitor the severity and progression of cognitive decline in PD.<\/jats:p>","DOI":"10.3233\/jpd-212535","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T14:15:03Z","timestamp":1619792103000},"page":"1117-1127","source":"Crossref","is-referenced-by-count":47,"title":["Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson\u2019s Disease"],"prefix":"10.1177","volume":"11","author":[{"given":"Ling-Zhi","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Neurology, Qingdao Municipal Hospital, Qingdao University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[{"name":"Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Qingdao Municipal Hospital, Qingdao University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ning","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Qingdao Municipal Hospital, Qingdao University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Tai","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-212535_ref1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: The inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212535_ref2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/01.wnl.0000338632.00552.cb","article-title":"Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest study","volume":"72","author":"Aarsland","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JPD-212535_ref3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","article-title":"Cognitive profile of patients with newly diagnosed Parkinson disease","volume":"65","author":"Muslimovic","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JPD-212535_ref4","doi-asserted-by":"crossref","first-page":"eaam6003","DOI":"10.1126\/scitranslmed.aam6003","article-title":"Finding useful biomarkers for Parkinson\u2019s disease","volume":"10","author":"Chen-Plotkin","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.3233\/JPD-212535_ref5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","article-title":"Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease","volume":"15","author":"Ng","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JPD-212535_ref6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JPD-212535_ref7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"10.3233\/JPD-212535_ref8","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: A biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JPD-212535_ref9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-019-0265-2","article-title":"Neurofilament light chain - new potential for prediction and prognosis","volume":"15","author":"Fyfe","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JPD-212535_ref10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson Progression Marker Initiative (PPMI)","volume":"95","author":"Initiative PPM","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.3233\/JPD-212535_ref11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.parkreldis.2020.04.009","article-title":"Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson\u2019s disease","volume":"74","author":"Sampedro","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212535_ref12","doi-asserted-by":"crossref","first-page":"14114","DOI":"10.1038\/s41598-017-14179-1","article-title":"Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington\u2019s disease R6\/2 mice","volume":"7","author":"Soylu-Kucharz","year":"2017","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-212535_ref13","first-page":"1277","article-title":"Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-212535_ref14","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.dadm.2018.07.002","article-title":"Derivation of cutoffs for the Elecsys(\u00ae) amyloid \u03b2 (1-42) assay in Alzheimer\u2019s disease","volume":"10","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JPD-212535_ref15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: The Parkinson\u2019s Progression Markers Initiative study","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-212535_ref16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.parkreldis.2017.02.008","article-title":"Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson\u2019s disease","volume":"38","author":"Hendershott","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212535_ref17","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/mds.23362","article-title":"A recommended scale for cognitive screening in clinical trials of Parkinson\u2019s disease","volume":"25","author":"Chou","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212535_ref18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.parkreldis.2016.03.006","article-title":"Longitudinal changes in cognition in early Parkinson\u2019s disease patients with REM sleep behavior disorder","volume":"27","author":"Chahine","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212535_ref19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212535_ref20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson\u2019s progression markers initiative (PPMI) - establishing a PD biomarker cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JPD-212535_ref21","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"10.3233\/JPD-212535_ref22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3233\/JAD-190069","article-title":"Impact of pre-analytical differences on biomarkers in the ADNI and PPMI studies: Implications in the era of classifying disease based on biomarkers","volume":"69","author":"Stewart","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JPD-212535_ref23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clinbiochem.2019.05.006","article-title":"Method comparison study of the Elecsys\u00aew \u03b2-Amyloid (1-42) CSF assay versus comparator assays and LC-MS\/MS","volume":"72","author":"Shaw","year":"2019","journal-title":"Clin Biochem"},{"key":"10.3233\/JPD-212535_ref24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.25811","article-title":"Evolution of Alzheimer\u2019s disease cerebrospinal fluid biomarkers in early Parkinson\u2019s disease","volume":"88","author":"Irwin","year":"2020","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-212535_ref25","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JPD-212535_ref26","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms","volume":"92","author":"Marques","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JPD-212535_ref27","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.28056","article-title":"CSF NFL in a longitudinally assessed PD cohort: Age effects and cognitive trajectories","volume":"35","author":"Lerche","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212535_ref28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.06.025","article-title":"Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson\u2019s disease","volume":"56","author":"O\u2019Keeffe","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212535_ref29","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JPD-212535_ref30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-212535_ref31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-212535_ref32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JPD-212535_ref33","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.42.7.1315","article-title":"Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson\u2019s disease","volume":"42","author":"Arai","year":"1992","journal-title":"Neurology"},{"key":"10.3233\/JPD-212535_ref34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: A cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-212535_ref35","first-page":"CD010803","article-title":"CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"3","author":"Ritchie","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JPD-212535_ref36","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/ene.13389","article-title":"Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: A neuropathology-based cohort","volume":"24","author":"Kovacs","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-212535_ref37","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","article-title":"Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia","volume":"87","author":"Rohrer","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JPD-212535_ref38","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/ene.13554","article-title":"Serum neurofilament light chain in patients with acute cerebrovascular events","volume":"25","author":"De Marchis","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-212535_ref39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-212535_ref40","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.4155\/bio-2019-0213","article-title":"Neuro biomarker levels measured with high-sensitivity digital ELISA differ between serum and plasma","volume":"11","author":"O\u2019Connell","year":"2019","journal-title":"Bioanalysis"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-212535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:49:47Z","timestamp":1777610987000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-212535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":40,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jpd-212535","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}